Dividends & Buybacks ·
At its 2026 Annual Meeting of Stockholders on June 12, 2026, Calidi Biotherapeutics, Inc. stockholders approved an…
CLDICalidi Biotherapeutics, Inc.
At its 2026 Annual Meeting of Stockholders on June 12, 2026, Calidi Biotherapeutics, Inc. stockholders approved an amendment to the certificate of incorporation to allow the Board of Directors to effect a reverse stock split within a range of 1-for-2 to 1-for-16. Stockholders also elected Scott Leftwich as a Class III Director and approved an appointment of CBIZ CPAs P.C. as the company's independent auditor. Calidi Biotherapeutics, Inc. is a biotechnology company focused on oncolytic virotherapy.***